Market reviews

Market review on human pharmaceuticals

Published on 6 February 2019

Finland is the most important individual market for Orion, generating about one-third of the Group’s net sales. According to IQVIA statistics, a significant share of Orion’s prescription drug sales in the Finnish pharmacy channel, approximately 69%, were reference priced drugs in 2018. The sales of Orion’s reference priced prescription drugs decreased slightly more than the market. The decline was mostly due to the change made in the pricing system for substitutable prescription drugs at the beginning 2017, which has been followed by toughened price competition. The average price of reference priced drugs in the market decreased during 2018 approximately 10% from the comparative period. The impact of price competition on Orion has been significant due to the Company’s broad product range and significant market share in Finland. The total sales of Orion’s human pharmaceuticals, including both medicinal and non-medicinal products, was clearly behind market trend in 2018. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while they only account for a small share of Orion’s net sales in Finland.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Source: IQVIA 1-12/2018

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. There was no major change in its market share compared to the previous year. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Orion's market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Source: IQVIA pharmaceutical sales statistics 1-12/2018

Orion is a significant player also in the Scandinavian generics market.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. In 2018, Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Source: IQVIA pharmaceutical sales statistics MAT9/2018
Europe TOP 5: Germany, United Kingdom, France, Spain and Italy

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2018 were up by 3% at EUR 558 (540) million. According to IQVIA pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 5% at EUR 64 (61) million in Europe.

***

Published on 24 October 2018

Finland is the most important individual market for Orion, generating about one-third of the Group's net sales. According to IQVIA statistics, a significant share of Orion's prescription drug sales in the Finnish pharmacy channel, approximately 68%, were reference priced drugs in January–September 2018. The sales of Orion’s reference priced prescription drugs decreased slightly more than the market. The decline was mostly due to the change made in the pricing system for substitutable prescription drugs at the beginning 2017, which was followed by toughened price competition. The average price of reference priced drugs has decreased during 2018 approximately 10% from the comparative period. The impact of price competition on Orion has been significant due to the company's broad product range and significant market share in Finland.

The total sales of Orion's human pharmaceuticals, including both medicinal and non-medicinal products, was clearly behind market trend in January–September 2018. The growth in the Finnish pharmaceuticals market has mostly been generated by proprietary products, while proprietary products only account for a small share of Orion's net sales in Finland.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Source: IQVIA 1-9/2018

Despite the challenging operating environment, Orion has maintained its position as leader in marketing pharmaceuticals in Finland. Orion has a particularly strong position in reference priced prescription drugs and in self-care product sales, with its market share being a quarter of the market in each.

Orion's market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Source: IQVIA pharmaceutical sales statistics 1-9/2018

Orion is a significant player also in the Scandinavian generics market.

 The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for 11% of the Group’s net sales in January–September 2018.

Total sales of Orion’s branded Parkinson’s drugs:

Source: IQVIA pharmaceutical sales statistics MAT6/2018 (7/2017–6/2018)
Europe TOP 5: Germany, United Kingdom, France, Spain and Italy

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2018 were up by 3% at EUR 553 (537) million. According to IQVIA pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 10% at EUR 64 (58) million in Europe.

***

Published on 18 July 2018

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IQVIA statistics, Finnish sales of human pharmaceuticals, including medicinal and non-medicinal products, in January–June 2018 increased 9% on the corresponding period of the previous year. Orion's human pharmaceutical sales in Finland were down by 8%, mainly due to the change made in the Finnish pricing system for substitutable prescription drugs at the beginning of 2017, which has toughened price competition. A significant share of Orion's prescription drug sales, 60%, were reference priced drugs. In the Finnish pharmaceuticals market, the sales of reference priced drugs were down by 8% and Orion's reference priced drugs by 9%.

Sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Despite the challenging operating environment Orion has maintained its position as leader in marketing pharmaceuticals in Finland: its share of the medicinal and non-medicinal products market was 12% in January–June 2018. Orion has a particularly strong standing in the pharmacy sales of self-care products and in reference priced prescription drugs.

Orion's market share in the sales of human pharmaceuticals in Finland (medicinal and non-medicinal products):

Source: IQVIA: 1-6/2018

Orion is a significant player also in the Scandinavian generics market, where according to IQVIA statistics, it was among the top three generic companies in all of its operating countries in 2017. Biosimilars are an important source of growth for generic drugs in the area.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for 12% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Europe TOP 5: Germany, United Kingdom, France, Spain and Italy.

Sales of Orion’s branded Parkinson’s drugs decreased due to generic competition and changes in exchange rates.

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2018 were up by 3% at EUR 548 (532) million. According to IQVIA pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 21% at EUR 65 (54) million in Europe.

****

Published on 24 April 2018

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IQVIA statistics, Finnish sales of human pharmaceuticals, including medicinal and non-medicinal products, in January-March 2018 totalled EUR 652 (589) million, up by 11% on the corresponding period of the previous year. According to IQVIA statistics, Orion's human pharmaceutical sales in Finland, including medicinal and non-medicinal products, totalled EUR 79 (84) million in January-March 2018, down by 6% on the corresponding period of the previous year. Orion's prescription drug sales was down by 11% at EUR 52 (59) million, while Orion's self-care product sales increased by 6% at EUR 26 (25) million. Of Orion's prescription drug sales, 59%, or EUR 31 (34) million were reference priced drugs. In the Finnish pharmaceuticals market, the sales of reference priced drugs were down by 7% and Orion's reference priced drugs were down by 9%, mainly due to the change made to the pricing system for substitutable prescription drugs at the beginning of 2017 in the Finnish market.

Orion maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IQVIA, Orion's market share of pharmaceuticals (including medicinal and non-medicinal products) in Finland in January-March 2018 was 12% (14%). Its market share of prescription drugs was 10% (12%), of reference priced prescription drugs 27% (28%) and of self-care products 24% (24%).

Orion is a significant player also in the Scandinavian generic market, where it was among the top three generic players in all of its operating countries in 2017. Biosimilars are an important source of growth for generic drugs in Scandinavia, where according to IQVIA the market for generic and self-care products grew by 9% in 2017. Orion's growth was 8%. Adding biosimilars to this, Orion grew faster than the market: in Scandinavia, market growth was 21% and Orion's growth 34%. In the Finnish market, biosimilars have been adopted more slowly than in other Nordic countries: in 2017, the biosimilar market only grew by 1% and Orion's sales were at the previous year's level.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for just over 10% of the Group’s net sales.

Total sales of Orion’s branded Parkinson’s drugs:

Sales of Orion’s branded Parkinson’s drugs decreased due to generic competition.

According to IQVIA pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in December 2017 were up by 4% at EUR 542 (522) million. According to IQVIA pharmaceutical sales statistics, sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 32% at EUR 63 (48) million in Europe.